We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+10.05%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$630M
AUM Growth
+$66.5M
Cap. Flow
+$74.6M
Cap. Flow %
11.85%
Top 10 Hldgs %
30.71%
Holding
120
New
23
Increased
22
Reduced
38
Closed
13

Top Buys

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$79.9M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$14.1M
3
MRK icon
Merck
MRK
+$12.3M
4
AGN
Allergan plc
AGN
+$6.72M
5
BMY icon
Bristol-Myers Squibb
BMY
+$6.42M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$20M
2
PFE icon
Pfizer
PFE
+$13.2M
3
MDT icon
Medtronic
MDT
+$11M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$8.02M
5
CPHD
Cepheid Inc
CPHD
+$8M

Sector Composition

Rank Sector Weight
1 Healthcare 86.01%
2 Financials 0.83%
3 Technology 0.09%
4 Energy 0.06%
5 Industrials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ENDP
26
DELISTED
Endo International plc
ENDP
$7.26M 1.15%
360,200
-275,000
-43% -$5.47M
HOLX
27
DELISTED
Hologic
HOLX
$6.99M 1.11%
180,000
– –
VRTX icon
28
Vertex Pharmaceuticals
VRTX
$126B
$6.98M 1.11%
80,013
+20,013
+33% +$1.89M
ABBV icon
29
AbbVie
ABBV
$435B
$6.94M 1.1%
110,000
+40,000
+57% +$2.59M
NKTR icon
30
Nektar Therapeutics
NKTR
$2.58B
$6.7M 1.06%
26,000
-5,333
-17% -$1.37M
SUPN icon
31
Supernus Pharmaceuticals
SUPN
$2.77B
$6.68M 1.06%
270,000
-10,000
-4% -$226K
EW icon
32
Edwards Lifesciences
EW
$51.7B
$6.63M 1.05%
165,000
-45,000
-21% -$1.69M
HZNP
33
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$6.62M 1.05%
365,000
-5,000
-1% -$97.7K
ZLTQ
34
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$6.28M 1%
160,000
– –
DXCM icon
35
DexCom
DXCM
$32B
$5.7M 0.91%
260,000
+40,000
+18% +$890K
ELGX
36
DELISTED
Endologix Inc
ELGX
$5.57M 0.88%
43,500
– –
XNCR icon
37
Xencor
XNCR
$1.55B
$5.51M 0.88%
225,000
– –
CNC icon
38
Centene
CNC
$32.5B
$5.36M 0.85%
160,000
-63,424
-28% -$2.2M
IOVA icon
39
Iovance Biotherapeutics
IOVA
$2.87B
$5.35M 0.85%
650,000
– –
WBA
40
DELISTED
Walgreens Boots Alliance
WBA
$5.24M 0.83%
65,000
-300
-0.5% -$24.5K
NVRO
41
DELISTED
NEVRO CORP.
NVRO
$5.15M 0.82%
49,300
-5,000
-9% -$452K
RIGL icon
42
Rigel Pharmaceuticals
RIGL
$750M
$5.14M 0.82%
140,000
+55,000
+65% +$1.58M
KITE
43
DELISTED
Kite Pharma, Inc.
KITE
$5.03M 0.8%
90,000
+20,000
+29% +$1.11M
AET
44
DELISTED
Aetna Inc
AET
$4.85M 0.77%
42,000
-25,000
-37% -$2.93M
OMCL icon
45
Omnicell
OMCL
$1.68B
$4.54M 0.72%
118,537
-10,000
-8% -$373K
HUM icon
46
Humana
HUM
$46.2B
$4.42M 0.7%
25,000
-5,000
-17% -$868K
COR icon
47
Cencora
COR
$61.2B
$4.28M 0.68%
53,000
-25,000
-32% -$2.14M
CAH icon
48
Cardinal Health
CAH
$55.4B
$4.27M 0.68%
55,000
-27,000
-33% -$2.18M
MGNX icon
49
MacroGenics
MGNX
$257M
$4.19M 0.67%
140,000
– –
MCK icon
50
McKesson
MCK
$101B
$4.17M 0.66%
25,000
-5,000
-17% -$932K
1
2
3 4 5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q3 2016 Portfolio in Review

As of Q3 2016, Rhenman & Partners Asset Management held 120 positions worth $630M, up 12% from $563M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Rhenman & Partners Asset Management deployed $74.6M of net new capital in Q3 2016, opening 23 new positions and adding to 22 existing holdings. Its largest new stake was Shire pic: 409,858 shares worth $26.6M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 94% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $8.02M trimmed.

  • Rhenman & Partners Asset Management's largest Q3 2016 buy was Shire pic: 409,858 shares worth $26.6M.
  • Rhenman & Partners Asset Management added most to Allergan plc in Q3 2016, an estimated $6.72M increase.
  • Rhenman & Partners Asset Management's biggest Q3 2016 reduction was Regeneron Pharmaceuticals, cutting an estimated $8.02M.
  • Rhenman & Partners Asset Management fully exited Gilead Sciences in Q3 2016, selling an estimated $20M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 31% of its $630M portfolio in Q3 2016.
  • Rhenman & Partners Asset Management opened 23 new positions and closed 13 in Q3 2016.
  • Rhenman & Partners Asset Management's portfolio value rose 12% quarter-over-quarter to $630M.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2016, filed 8 Nov 2016.